Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Asciminib has the potential to succeed where other TKIs have failed in CML

Tyrosine kinase inhibitors (TKIs) are some of the most successful drugs available for the treatment of a myriad hematological cancers. However, they are not perfect, as patients can relapse or develop refractory cancers. In this video, Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, outlines the development of a new TKI, asciminib, which has shown to be effective in patients with chronic myeloid leukemia (CML) resistant to two or more previous TKIs (NCT03106779). Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Dr Mauro mentions the aims for the third phase of the trial and his high hopes for this drug in the future.